Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 76.9%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 191,900 shares, a growth of 76.9% from the February 13th total of 108,500 shares. Currently, 10.0% of the company’s stock are sold short. Based on an average daily volume of 804,500 shares, the days-to-cover ratio is presently 0.2 days.

Vincerx Pharma Stock Performance

Shares of VINC opened at $0.82 on Friday. The firm has a market cap of $1.84 million, a PE ratio of -0.04 and a beta of 1.43. The firm’s 50 day moving average price is $1.82 and its 200 day moving average price is $6.21. Vincerx Pharma has a twelve month low of $0.75 and a twelve month high of $151.80.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.